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Abstract: A spontaneous mutation in the lysosomal acid phosphatase (Acp2) enzyme (nax:
naked–ataxia) in experimental mice results in delayed hair appearance and severe cytoarchitectural
impairments of the cerebellum, such as a Purkinje cell (PC) migration defect. In our previous
investigation, our team showed that Acp2 expression plans a significant role in cerebellar development.
On the other hand, the dopaminergic system is also a player in central nervous system (CNS)
development, including cerebellar structure and function. In the current investigation, we have
explored how Acp2 can be involved in the regulation of the dopaminergic pathway in the cerebellum
via the regulation of dopamine receptor expression and patterning. We provided evidence about
the distribution of different dopamine receptors in the developing cerebellum by comparing the
expression of dopamine receptors on postnatal days (P) 5 and 17 between nax mice and wild–type
(wt) littermates. To this aim, immunohistochemistry and Western blot analysis were conducted using
five antibodies against dopamine receptors (DRD1, –2, –3, –4, and –5) accompanied by RNAseq data.
Our results revealed that DRD1, –3, and –4 gene expressions significantly increased in nax cerebella
but not in wt, while gene expressions of all 5 receptors were evident in PCs of both wt and nax
cerebella. DRD3 was strongly expressed in the PCs’ somata and cerebellar nuclei neurons at P17 in
nax mice, which was comparable to the expression levels in the cerebella of wt littermates. In addition,
DRD3 was expressed in scattered cells in a granular layer reminiscent of Golgi cells and was observed
in the wt cerebella but not in nax mice. DRD4 was expressed in a subset of PCs and appeared to
align with the unique parasagittal stripes pattern. This study contributes to our understanding of
alterations in the expression pattern of DRDs in the cerebellum of nax mice in comparison to their wt
littermates, and it highlights the role of Acp2 in regulating the dopaminergic system.
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1. Introduction
The cerebellum has a crucial function in coordinating motor output, adapting involuntary reflexes,
and regulating cognitive function [1–3]. Any alteration in the cerebellar structure and/or function,
both during development and beyond, can contribute to a variety of movement and neuropsychiatric
disorders and developmental syndromes [4–6]. Several of these disorders are associated with alterations
in lysosomes and their acid hydrolases [7–9].
Lysosomes are membrane–bound organelles providing a perfect acidic pH (pH < 5) for degrading
macromolecules [10–12]. Lysosomes contain over 50 different soluble acid hydrolases [13,14], such as
lysosomal acid phosphatase 2 (ACP2), that play a pivotal role in the development of the cerebellum.
ACP2 is commonly expressed in all mice organs, including the brain and cerebellum [9]. In the
cerebellum, ACP2 is strongly expressed in cerebellar Purkinje cells (PCs) [9,15]. The significance of
proper lysosomal function is disclosed by several human diseases, including neurodevelopmental
and degenerative diseases, that occur as a result of mutations in lysosomal enzymes [7,16]. Mice that
have experienced a targeted disruption of Acp2 exhibit a mild phenotype with generalized lysosomal
storage in the kidneys and central nervous system (CNS) [17]. A spontaneous autosomal recessive
point mutation in the Acp2 gene (nax: naked–ataxia) leads to several phenotypic abnormalities, weight
loss, skin malformations, decreased size of the brain, and underdeveloped cerebellum, including
cerebellar cortex disorganization with excessive PC migration and the disrupted compartmentation
organization [16,18].
In the CNS, dopamine plays a crucial role in motor and cognitive functions [19,20], but whether
the extent of the expression of dopamine receptors (DRDs) in the cerebellum regulates these functions is
unclear. It has been shown that ACP2 is associated with progressive supranuclear palsy (PSP), which is
an atypical parkinsonian condition [21]. Symptoms of PSP appear to originate from dysfunctions of
multiple neurotransmitter systems, including dopaminergic systems [22–25].
Although the cerebellum has a unique role in movement and posture control, it was considered
to be a nondopaminergic region for many years. Recently, it has been reported that dopaminergic
projections to the cerebellar cortex and nuclei originate mostly from the ventral tegmental area (VTA),
and most DRDs are present in PCs, which probably affects PC plasticity [26–28]. Implementation
of anterograde and retrograde axonal tracing along with tyrosine hydroxylase immunofluorescence
histochemistry revealed that the VTA in rat dispatches dopaminergic fibers that terminate in the granule
and the Purkinje cell layer (gcl and Pcl, respectively) [26,27]. A comparable study between lurcher
mice with 100% loss of cerebellar Purkinje cells and wild–type (wt) control mice demonstrated that,
on the contrary to what happened in wt mice, cerebellar stimulation failed to evoke prefrontal cortex
dopamine efflux in lurcher mice, indicating a dependency on cerebellar PC outputs [29]. According
to the available data, dopamine–active transporter (DAT) immunoreactive axons present in specific
lobules of the cerebellar vermis in primates primarily innervate the gcl and the adjacent Pcl [30].
Studies have illustrated that the cerebellum expresses all dopamine receptors (DRD1–5) [20,31,32].
In mice, DRD1 and –5 proteins have shown to be expressed in PCs and the molecular layer (mL),
DRD2, in all cerebellar cortical layers (ml, Pcl, and gcl); DRD3 mostly in the Pcl and ml of lobules
IX and X; and DRD4 in the ml of the cerebellum [30]. Furthermore, the presence of mRNA for the
dopamine receptor subtypes has been demonstrated in the cerebellum [31–33]. One point worth
mentioning is that nax mice exhibit mild to severe alterations in their gene expression patterns in the
developing cerebellum [16], displaying the potential alteration of DRDs’ genes expression patterns in
the cerebellum.
This study aims to compare the expression levels of DRDs in the cerebellum of nax mice and their
wt control littermates in order to identify the effects of ACp2 mutation on the dopaminergic system
and, specifically, its contribution to cerebellar development. Our findings provide novel insights on
the differential expression of DRDs during the cerebellar development of mice.
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2. Materials and Methods
2.1. Animal Maintenance
All animal procedures were performed in accordance with institutional regulations and the
Guide to the Care and Use of Experimental Animals from the Canadian Council for Animal Care and has
been approved by local authorities, “the Bannatyne Campus Animal Care Committee”, University
of Manitoba (approved protocol #15066). A colony of nax mutant mice was established in the
Genetic Model Center at the University of Manitoba by breeding mice (C57BL/6) heterozygous for the
nax mutation (homozygote/heterozygote/wt ratio was ∼25%:50%:25%, respectively). Animals were
grouped (n = 8 for each group) in standard polycarbonate cages with dust–reduced wood shavings
as bedding. Animals were housed in groups of three per cage in a 12/12–h light/dark cycle (light on
between 7:00 a.m. and 7:00 p.m.) with free access to chow and tap water. The animals were randomly
allocated to different experimental groups.
2.2. Immunohistochemistry (IHC)
Peroxidase immunohistochemistry were carried out on cerebellar sections according to our lab
protocol, as described previously [18,34]. Briefly, at two postnatal ages of P5 or P17, animals were
transcardially perfused with 10–20 ml of 4% paraformaldehyde in 0.1–M phosphate buffer, pH 7.4.
Brains were then dissected free and post–fixed overnight in the same fixative and cryoprotected with
10%, 20%, or 30% sucrose in the optimal cutting temperature (O.C.T.) compound. Free–floating sections
were processed for light microscopic level studies, as described previously. All antibodies were diluted
in 0.1–M phosphate–buffered saline (PBS, Gibco, Billings, MT, USA) with 10% normal goat serum
and 0.3% Triton X–100. Sections were exposed overnight to overnight with primary affinity–purified
antibody to one of the dopamine receptors (DRD1, DRD2, DRD3, DRD4, or DRD5 (1:1000)), followed
by washing and secondary antibody exposure (goat anti–rabbit IgG or biotinylated goat anti–rabbit
antibody (1:200; Jackson, West Grove, PA, United States). The reaction was developed by using either
0.05% diaminobenzidine or 0.01% hydrogen peroxide reaction.
2.3. Primary Antibodies Used for IHC and WB Analysis
Primary antibodies used to detect the five dopamine receptors. D1: rabbit polyclonal anti–D1
dopamine receptor (TA328798, anti–Drd1, diluted 1:1000; OriGene Biotech Co., Rockville, MD, USA);
D2: rabbit polyclonal anti–D2 dopamine receptor (TA328800, anti–Drd2, diluted 1:1000; OriGene
Biotech Co., Rockville, MD, USA), produced against recombinant rat dopamine receptor 2 (DR2); D3:
rabbit polyclonal anti–D3 dopamine receptor (TA328800, anti–Drd3, diluted 1:1000; OriGene Biotech
Co., Rockville, MD, USA), produced against recombinant rat dopamine receptor 3 (DR3); D4: rabbit
polyclonal anti–D4 dopamine receptor (TA321202, anti–DRD4, diluted 1:1000; OriGene Biotech Co.,
Rockville, MD, USA), produced against recombinant rat dopamine receptor D4 (DRD4); and D5: rabbit
polyclonal anti–D5 dopamine receptor (TA328802, anti–Drd5, diluted 1:1000; OriGene Biotech Co.,
Rockville, MD, USA), produced against recombinant rat dopamine receptor 5 (DR5).
2.4. Protein Extraction and Western Blot Analysis
The animals were sacrificed at P5 or P17, and cerebella were extracted. The following steps
were performed to evaluate expression levels of the dopamine receptors (DRD1, DRD2, DRD3, DRD4,
and DRD5). After sonication of the samples, protein concentration was measured by using a BCA
protein assay kit (cat#5000121, Bio–Rad, Hercules, CA, USA). The protein sample was suspended
in loading buffer [Tris–HCl 60mM, glycerol 25%, SDS 2%, mercaptoethanol (ME), (Thermo Fischer
Scientific, Mississauga, ON, Canada)] 14.4mM, bromophenol blue 0.1%, and H2O) and separated
by sodium dodecyl sulfate polyacrylamide gel electrophoresis. Based on the molecular weight of
the protein, an 8%–15% polyacrylamide gel was used for electrophoresis. Twelve microliters of each
sample was loaded, and 5–µl precision plus protein was used as the marker standard (Thermo Fischer
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Scientific, Mississauga, ON, Canada). The protein was then transferred to a polyvinylidene fluoride
membrane. Then, blots were incubated with blocking solution, followed by overnight incubation with
the primary antibody (see previous paragraph for details). After being washed, blots were incubated
with horse radish peroxidase–conjugated antibody, and finally, immunoreactivity of polypeptides was
detected using an enhanced chemiluminescence (ECL) solution. Quantification of the results was
performed by densitometry (bands were scanned and analyzed by ImageJ software). All bands were
normalized to β–actin expression.
2.5. RNA Isolation and Analyses
The cerebella of nax (P5, n = 2 and P7, n = 3) and wt littermates (P5, n = 3 and P7, n = 3) were
dissected, and total RNA was extracted using the RNeasy Plus Mini Kit (Catalog No. 74134, QIAGEN,
Hilden, Germany). RNA product concentration was measured by Nano–Drop ND–1000 UV–Vis
Spectrophotometer (Thermo Fisher Scientific, Waltham, MA, USA). The samples were kept at −80 ◦C
and sent to the McGill University and Genome Quebec Innovation Centre (MUGQIC). Raw RNAseq
data were analyzed with FASTQ, and files were filtered and trimmed using the fastp package [35].
Then, the cleaned data were aligned with the mouse reference genome (GRCm38.97) using the Subjunc
Aligner [36]. Next, low–quality alignments, duplicates, and nonaligned sequences were removed from
the aligned files using Samtools [25]. Finally, the number of reads associated with each gene on the
reference genome was extracted and counted using FeatureCounts software [37], and the Reads Per
Kilobase of transcript per Million mapped reads (RPKM) was calculated for each gene.
2.6. Statistical Analysis
GraphPad Prism 7.05 was used to analyze the difference by two–way analysis of variance (ANOVA)
for more than two groups and by a Student’s t–test for comparison of the two groups. Differences were
considered to be statistically significant when p < 0.05 and are indicated in the figures as *(p < 0. 05)
and **(p < 0.01).
2.7. Imaging
Images were captured by using a Zeiss Axio Imager M2 microscope (Zeiss, Toronto, ON, Canada).
Images were cropped, corrected for brightness and contrast, and assembled into montages using
Adobe Photoshop CS5 Version 12.
3. Results
In order to understand whether the DRDs are altered, RNA sequencing was performed in nax
(n = 5) and wt (n = 6) cerebellum at P5 and P7 (P5/P7). RNAseq at P5/P7 revealed Drd1, Drd3, and Drd4
were significantly increased in the nax cerebellum compared to wt cerebellum. Although Drd2 and Drd5
expression increased in the nax cerebellum, it was not statistically significant from the wt littermates
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Figure 1. RNA sequencing data analysis in nax (n = 5) and wild–type (wt) (n = 6) mice. Data analysis 
shows dopamine receptor D1 (Drd1, A), Drd3 (C), and Drd4 (D) are significantly increased in the nax 
cerebellum. Although an increase in Drd2 (B) and Drd5 (E) is apparent, statistical significance was not 
reached. The data in the bar graph are presented as the mean ± SEM, and statistical analysis was 
performed using an unpaired t–test (*p <0.05 and **p<0.01). RPKM: Reads Per Kilobase of transcript 
per Million mapped reads. 
3.1. Dopamine Receptor D1 (DRD1) Expression in wt and nax Cerebella at P5 and P17 
Immunoperoxidase staining of cerebellar sections for DRD1 in wt (Figure 2A) and nax mice 
(Figure 2B) was compared at P5. Immunoreactivity was observed primarily in the cerebellar cortex 
and white matter. DRD1 in the nax cerebellum showed similar expression as in the wt littermates, 
and immunoreactivity was seen in the Purkinje cell layer (Pcl) and white matter (wm) but not in the 
external germinal zone (egz) and granular layer (gl). By P17, DRD1 immunoreactivity was broadly 
present in all three layers of the cerebellar cortex, particularly in the gl, PC somata in the Pcl, and in 
dendrites residing in the molecular layer (mL), but not in the wm of wt controls (Figure 2C). DRD1 
was primarily expressed in PC somata in the Purkinje cell/molecular layer (Pcl/mL; referred to as 
such, because PCs have invaded into the mL) but not as much in the gl (as compared to wt) in the nax 
cerebellum at P17 (Figure 2D). DRD1 immunoreactivity was weakly detected in cerebellar nuclei 
neurons in the nax cerebellum, which was similar to the wt littermates at P17 (data not shown). 
Western blot analysis revealed no significant differences in total cerebellar DRD1 protein expression 
between both groups at P5 and P17 (Figure 2E). Interestingly, RNAseq at P5/P7 revealed a significant 
upregulation in Drd1 RNA transcript in the nax as compared to the wt cerebellum (Figure 1A). 
Figure 1. Cont.
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Figure 1. RNA sequencing data analysis in nax (n = 5) and wild–type (wt) (n = 6) mice. Data analysis
shows dopamine receptor D1 (Drd1, A), Drd3 (C), and Drd4 (D) are significantly increased in the nax
cerebellum. Although an increase in Drd2 (B) and Drd5 (E) is apparent, statistical significance was
not reached. The data in the bar graph are presented as the mean ± SEM, and statistical analysis was
performed using an unpaired t–test (* p < 0.05 and ** p < 0.01). RPKM: Reads Per Kilobase of transcript
per Million mapped reads.
3.1. Dopamine Receptor D1 (DRD1) Expression in wt and nax Cerebella at P5 and P17
Immunoperoxidase staining of cerebellar sections for DRD1 in wt (Figure 2A) and nax mice
(Figure 2B) was compared at P5. Immunoreactivity was observed primarily in the cerebellar cortex
and white matter. DRD1 in the nax cerebellum showed similar expression as in the wt littermates,
and immunoreactivity was seen in the Purkinje cell layer (Pcl) and white matter (wm) but not in the
external germinal zone (egz) and granular layer (gl). By P17, DRD1 immunoreactivity was broadly
present in all three layers of the cerebellar cortex, particularly in the gl, PC somata in the Pcl, and in
dendrites residing in the molecular layer (mL), but not in the wm of wt controls (Figure 2C). DRD1
was primarily expressed in PC somata in the Purkinje cell/molecular layer (Pcl/mL; referred to as
such, because PCs have invaded into the mL) but not as much in the gl (as compared to wt) in the
nax cerebellum at P17 (Figure 2D). DRD1 immunoreactivity was weakly detected in cerebellar nuclei
neurons in the nax cerebellum, which was similar to the wt littermates at P17 (data not shown).
Western blot analysis revealed no significant differences in total cerebellar DRD1 protein expression
between both groups at P5 and P17 (Figure 2E). Interestingly, RNAseq at P5/P7 revealed a significant
upregulation in Drd1 RNA transcript in the nax as compared to the wt cerebellum (Figure 1A).
3.2. Dop mine Receptor D2 (DRD2) Expression in wt and nax Cerebella at P5 and P17
Immunohistochemistry using a DRD2 antibody showed immunoperoxidase reactivity in the
cerebellar cortex on both P5 and P17. By P5, DRD2 is weakly expressed in Pcl and egz of the wt
littermate cerebellum (Figure 3A), whereas a relatively strong expression was observed in PC somata
of the nax cerebellum (Figure 3B). By P17, DRD2 expression in the cerebellar cortex was localized
mostly in PC somata and the ml but not in the gcl, which was comparable between wt (Figure 3C) and
nax (Figure 3D) cerebella. Western blot analysis was performed at P5 and P17 using lysates of total
wt and nax cerebella, and it showed a trend towards a slight increase in DRD2 expression, although
these differences did not reach significance (Figure 3E). Similarly, RNAseq at P5/P7 did not reveal a
significant increase in Drd2 gene expression in the nax cerebellum; thus, there were no significant
differences in DRD2 expression between nax and wt cerebella (Figure 1B).
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immunoreactivity as in the wt littermates at P5. (C) DRD1 immunostaining of the frontal sections of 
the wt cerebellum at P17 shows immunoreactivity in the Purkinje cell (PC) somata, the Pcl, and 
dendrites in the molecular layer (ml) and in the gl but not in the wm. (D) DRD1 immunostaining of 
the frontal sections of the nax cerebellum on P17 shows immunoreactivity in the PCs in the ml/Pcl. (E) 
Western blot analysis of whole cerebellar lysates revealed no significant differences in DRD1 
expression between wt and nax cerebella at P5 and P17 (wt: n = 3 and nax: n = 3). The data in the bar 
graphs are presented as the means of three independent experiments ± SEM, and statistical analysis 
was performed using a two–way ANOVA. P; postnatal. Scale bars: 100 μm in A, B, C, and D. 
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Figure 2. Fro t i s of wt and nax mouse cerebella: DRD1 expression at P5 and P17.
(A) Immunoperoxidase stai ing for RD1 in the wt cerebellum on P5 shows the immunoreactivity in
the Purkinje cel layer (Pcl) and white matter (wm) but not in th external germinal zon (egz) and
granular layer (gl). (B) Immunoperoxi t i i f r RD1 in the nax cerebellum shows similar
im unoreactivity as in the wt littermates at P5. (C) DRD1 im unostaining of the frontal sections of the
wt cerebellum at P17 shows immunoreactivity in the Purkinje cell (PC) somata, the Pcl, and dendrites
in the molecular layer (ml) and in the gl but not in the wm. (D) DRD1 immunostaining of the frontal
sections of the nax cerebellum on P17 shows immunoreactivity in the PCs in the ml/Pcl. (E) Western
blot analysis of whole cerebellar lysates revealed no significant differences in DRD1 expression between
wt and nax cerebella at P5 and P17 (wt: n = 3 and nax: n = 3). The data in the bar graphs are presented
as the means of three independent experiments ± SEM, and statistical analysis was performed using a
two–way ANOVA. P; postnatal. Scale bars: 100 µm in A, B, C, and D.
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both in wt (Figure 3A) and nax (Figure 4B) cerebella. Whereas, at P17, DRD3 immunoreactivity was 
detectable in the whole cortex of the wt cerebellum and was strongly and uniformly expressed in PC 
somata (Figure 4C, D). In addition, DRD3 immunoreactivity was detected in scattered cell bodies, 
similar in appearance to Golgi cells, in the gl (indicated arrows in Figure 4D(d)). Cerebellar nuclei 
neurons (CNs) were strongly immunopositive to DRD3 (Figure 4C, E). In the nax cerebellum at P17, 
strong DRD3 expression was observed in the cerebellar cortex and CNs (Figure 4F). In addition, 
DRD3 was present in multilayered PC somata in the Pcl/ml (due to excessive PC migration to mL) 
(Figure 4F, G), whereas there was no or only very little scattered immunoreactivity observed in the 
Figure 3. Frontal sections of wt and nax mouse cerebella: DRD2 expression at P5 and P17.
Immunoperoxidase staining for DRD2 in wt (A) and nax (B) cerebella at P5 shows weak immunoreactivity
in the Pcl of wt but relatively strong immunoreactivity in PC somata of the nax cerebellum.
(C,D) Immunoperoxidase staining for DRD2 in wt (C) and nax (D) cerebella at P17 shows weak
immunoreactivity in PCs, with no differences between the two groups. (E) Western blot analysis of
whole cerebellar lysates revealed no significant differences in DRD2 protein expression between wt and
nax cerebella at P5 and P17 (wt: n = 3 and nax: n = 3). The data in the bar graphs are presented as the
means of three independent experiments ± SEM; statistical analysis was performed using two–way
ANOVA. P; postnatal. Scale bars: 100 µm in A, C, and D and 50 µm in B.
3.3. Dopamine Receptor D3 (DRD3) Expression in wt and nax Cerebella at P5 and P17
Immunoperoxidase staining for DRD3 revealed weak expression in the cerebellar cortex at P5
both in wt (Figu e 3A) and nax (Figure 4B) cerebella. Whereas, at P17, DRD3 immunoreactivity was
de ectable in the whole cortex of the wt cer b llum and was strongly and uniformly xpressed in
PC somata (Figure 4C,D). In addition, DRD3 immunoreactivi y was detected in scatt red cell bodies,
i ilar in app arance to Golgi cells, in the gl (indicated arrows in Figur 4D(d)). Cerebellar nuclei
neurons (CNs) were str ngly immunopositive to DRD3 (Figure 4C,E). In the nax cer bellum at P17,
strong DRD3 expres ion was observed in the cerebellar cort x and CNs (Figure 4F). In addition,
DRD3 was present in multilayered PC somata in the Pcl/ml (due to exce sive PC migration to mL)
(Figure 4F,G), whereas there was no or only very little scattered immunoreactivity observed in the
cells similar to Golgi cells in the gl (Figure 4G,H). Western blot analysis showed comparable DRD3
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expressions in wt and nax cerebella at P5 and P17 (Figure 4I). Interestingly, however, RNAseq at P5/P7
revealed that Drd3 gene expression was significantly higher in nax than in wt cerebella (Figure 1C).
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3.4. Dopamine Rec ptor D4 (DRD4) Expressi i erebella on P5 and P17
At P5, weak DRD4 expression was detectable in the cerebellar cortex, mostly in the egz, of both
wt (Figure 5A) and nax (Figure 5B) cerebella. Whereas, at P17, DRD4 showed strong immunoreactivity
in the entire cerebellar cortex of wt mice (Figure 5C–G). In sagittal sections of the wt cerebellum, PC
somata immunoreactivity was strong in the nodular zone (NZ) but was lacking in the anterior zone
(AZ), while PC dendrites were immunopositive (Figure 5C). This pattern of gene expression was
aligned with the cerebellar zone and stripe cytoarchitecture. The cerebellum can be divided into four
transverse zones based on gene expression, afferents, and efferents: the anterior zone (AZ: lobules I–V),
the central zone (CZ: lobules VI–VII), the posterior zone (PZ: lobules VIII + dorsal lobule IX), and the
nodular zone (NZ: ventral lobule IX + lobule X). Additionally, each zone is subdivided into parasagittal
stripes (e.g., [15,16,18,38,39]). In the frontal section of the wt cerebellum, DRD4 expression was strongly
present in a subset of PCs (Figure 5D, black arrow heads), while no or only weak expression was
detectable in some of the other PCs (Figure 5D, arrow and white arrow head, respectively) at P17.
In addition, DRD4 expression in the wt cerebellum displayed a stripes pattern in lobules VIII and IX
(Figure 5E,F), while expression was uniform in PCs of lobule X (Figure 5G). In the nax cerebellum at
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P17, DRD4 showed immunoreactivity in a subset of PCs (indicated by black asterisks (Figure 4H)),
which was alternated with a weak or lack of DRD4 expression similar to the stripes pattern in lobule III
(Figure 5H, white asterisk). The same pattern was present in lobule IX (Figure 5I), whereas DRD4 was
uniformly expressed in PCs of lobule X (Figure 5J). Western blot analysis was performed at P5 and P17
using lysates of total wt and nax cerebella, and it showed a slight increase in DRD4 expression, although
these differences did not reach significance (Figure 5K). As for DRD1 and –3, RNAseq analysis at P5/P7
revealed that Drd4 gene expression was significantly higher in nax than in wt cerebella (Figure 1D).Int. J. Mol. Sci. 2020, 21, x FOR PEER REVIEW 10 of 18 
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(A,B) Immunoperoxidase staining for DRD4 in wt (A) and nax (B) cerebella at P5 shows immunoreactivity
in the external germinal zone (egz) and no or only weak immunoreactivity in the Pcl. (C–G) Sagittal
section of P17 wt cerebellum immunostained for DRD4 reveals strong immunoreactivity within the
cerebellar cortex. In the anterior zone, the expression of DRD4 is present in PC dendrites in the
molecular layer (ml), while PC somata and dendrites exhibit immunoreactivity in the nodular zone
(C). Frontal section of P17 wt cerebellum immunostained with DRD4 shows strong immunoreactivity
in a subset of PCs (indicated by black arrowheads), while another subset of PCs displays no (white
arrowhead) or only weak expression (arrow) in the cerebellar cortex (D). (E–G) Immunoperoxidase
staining for DRD4 in the wt cerebellum at P17 shows a striped expression pattern in lobule IXd (E,F)
and more uniform expression in PCs in lobule X (G). (H–J) DRD4 immunostaining of a frontal section
of the nax cerebellum at P17 shows immunoreactivity in a subset of PCs (asterisks) that follows a similar
stripes pattern in lobule III (H) and IX (I) but is uniform in lobule X (J). (K) Western blot analysis of
DRD4 expression in wt and nax cerebellum at P5 and P17 shows an apparent increase in expression in
nax cerebella at both time–points (wt: n = 3 and nax: n = 3); however, these differences did not reach
statistical significance. The data in the bar graphs are presented as the means of three independent
experiments ± SEM, and statistical analysis was performed using two–way ANOVA. P; postnatal. Scale
bars: 100 µm in A; 50 µm in B; 500 µm in C; 20 µm in D; 200 µm in E, F, G, H, and I; and 500 µm in J.
3.5. Dopamine receptor D5 (DRD5) expression in wt and nax cerebella on P5 and P17
Immunoperoxidase staining for DRD5 showed weak immunoreactivity in the Pcl of both wt
(Figure 6A) and nax (Figure 6B) cerebella at P5. A similar weak expression pattern in the Pcl,
with expression primarily localized in PCs, was observed at P17 for both groups (Figure 6C,D). Western
blot analysis was performed at P5 and P17 using lysates of total wt and nax cerebella and revealed a
slight increase in DRD5 expression, although these differences did not reach significance (Figure 6E).
Similarly, RNAseq at P5/P7 showed a relative increase in Drd5 gene expression in the nax cerebellum,
which was not significant (Figure 1E).Int. J. Mol. Sci. 2020, 21, x FOR PEER REVIEW 12 of 18 
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Figure 6. Sagittal sections of wt and nax mouse cerebella: DRD5 expression at P5 and P17.
(A,B) Immunoperoxidase staining for DRD5 in wt (A) and nax (B) cerebella at P5 shows weak
immunoreactivity in the Pcl. (C,D) Immunoperoxidase staining for DRD5 at P17 shows weak
immunoreactivity in PCs in the wt (C) and nax (D) cerebellar cortex. (E) Western blot analysis of whole
cerebellar lysates revealed no significant differences in DRD5 protein expression between wt and nax
cerebella at P5 and P17 (wt: n = 3 and nax: n = 3). The data in the bar graphs are presented as the
means of three independent experiments ± SEM, and statistical analysis was performed using two–way
ANOVA. P; postnatal. Scale bars: 50 µm in A and B and 100 µm in C and D.
4. Discussion
In this study, we used postnatal nax mice to determine whether anomalies of the cerebellar
cortex and PC degeneration and excessive migration are associated with alterations in the expression
patterns of various DRDs. Overall, the expression of DRDs in early postnatal development was
dynamic, from very weak and mostly localized in the Pcl (within the PC somata) and external
germinal zone (egz) to more strongly towards the whole cerebellar cortex, in which PCs express DRDs
uniformly—for instance, as for DRD3 or, in the characteristic parasagittal stripes pattern, as for DRD4.
Despite several apparent abnormalities and loss and excessive migration of PCs in the nax cerebellum,
there seemed to be no obvious (significant) differences in protein expression of the DRDs between nax
and wt littermate cerebella, especially when studying total cerebellar lysates. However, significant
differences were observed in gene expression levels of Drd1, Drd3, and Drd4 at P5/P7. The pattern of
the Drd3 and Drd4 expression appeared to be associated with the cerebellar cytoarchitecture changes
during postnatal development.
There is a significant body of anatomical evidence to support the existence of a direct connection
between the cerebellum and the dopaminergic mesencephalon [26,30]. Dopaminergic fiber projection
from the VTA to the cerebellar cortex, which is mainly terminated in the gl and Pcl, has been
demonstrated [27]. In addition, quantitative analyses revealed that DAT, which actively translocates
released dopamine from the synaptic cleft into the presynaptic neurons [40], is present in the cerebellum
and, in particular, in higher levels in the ml and cerebellar nuclei [41], which in itself is a sign that
dopamine and dopamine receptors exist in these sites. Based on their structural characteristics,
dopamine receptors are divided into two groups: D1–like (DRD1 and –5) and D2–like (DRD2, -3,
and -4) [42]. In the rat cerebellum, DRD1 and DRD5 were localized in PCs and the ml, DRD2 in all
layers, DRD3 mainly in the PCs and the ml of lobules IX and X, and DRD4 in the ml [30]. Another
study claimed that, in rat cerebellum, DRD1 was found only in PCs and the ml and DRD2 exclusively
in the ml of lobules IX and X [43]. These findings indicate that the exact expression profile of the
different DRDs in the cerebellum is still up for debate and requires further elucidation.
DRD1 is involved in mediating neuronal plasticity and has a prominent role in cognitive functions,
including learning and memory and spatial navigation [44–46]. Our results demonstrated that DRD1
was expressed in both the wt and nax cerebellar cortex. It is of particular interest to mention that, at P5,
no immunoreactivity at all was observed in the ml but that the PC somata and dendrites in the ml
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were immunoreactive at P17. This suggests that DRD1 is synthesized in the gl and Pcl and extended
toward the ml on PC dendrites during cerebellar development. Autoradiographic combined with in
situ hybridization techniques demonstrated that dopamine receptor binding, especially for the Drd1
subtype, occurs in both the ml and gl [27], while dopamine receptor mRNAs for both DRD1 and DRD2
subtypes are only present in the gl [27]. Thus, this implies that cerebellar dopamine receptors are
synthesized in the gl, perhaps in granule cell bodies, and are either transported through granule cell
axons to the ml to form presynaptic receptors or remain in granule cell bodies to constitute postsynaptic
receptors [27].
Rani and Kanungo claimed that the expression of DRD2 occurs at birth in both cerebral and
cerebellar cortices of mice. However, in the cerebellar cortex, a high expression of D2DR has been
reported at birth (at P0) [47]. Researchers also suggested that the Drd2 gene has a role in neuronal
maturation and dopaminergic synapse formation up to P15 of postnatal development of the murine
brain, during which the brain is still developing [47]. Paradoxically, our study indicates that, despite
the severe impairment in cerebellar cortex in nax mice, DRD2 expression is similar as in wt littermates
and that the neuronal maturation and synapse formation defects have no direct effect on DRD2
expression profiles. This does not exclude a functional role for DRD2 in neuronal maturation—or
any other developmental processes, for that matter; it simply indicates that expression levels are
unaltered under these specific conditions, which does not necessarily reflect receptor function or ligand
interaction dynamics.
A controversial functional aspect of DRD3 is its role as an autoreceptor, regulating the dopaminergic
activity of neurons [48]. In our study, although PC somata and cerebellar nuclei neuronal bodies were
strongly immunoreactive at P17, expression of DRD3 was very weak in both wt and nax at P5. It has
been shown that, in the Pcl, PCs expressed Drd3 mRNA, whereas dopamine binding sites were found
in the ml, where the dendritic trees of PCs are present [49,50]. Our results showed that, both in the
wt and nax cerebellum, DRD3 is strongly expressed in PCs and cerebellar nuclei neuronal bodies
but not in PC dendrites at the sites of the synapses with parallel fibers. This is particularly evident
in the nax cerebellum, in which, due to the dramatically decreased number of granule cells/parallel
fibers (the manuscript of this study is under review), PC somata are highly immunopositive for DRD3,
suggesting they autonomously express DRD3. In fact, RNAseq data show that the Drd3 gene expression
is significantly upregulated in the nax cerebellum. Furthermore, Golgi cells in the gl highly expresses
DRD3 but is absent or very weak in nax cerebellum. Therefore, this suggests that DRD3 may contribute
to a cerebellar cortex organization during postnatal corticogenesis as well.
Studies have reported the expression of DRD4 in the ml, in PCs, in stellate neurons of the ml, in a
few Golgi neurons of the gl, and in structures resembling climbing fibers [51,52]. In our current study,
DRD4 protein expression was slightly increased in nax mice cerebella. Despite the relatively weak DRD4
expression at P5, which was localized in the egz both in wt and nax cerebella, strong immunoreactivity
was evident in a subset of PC somata and dendrites at P17. The DRD4 expression profile in PC somata
and/or dendrites was different between the cerebella from wt and nax mice. For instance, only the PC
dendrites, but not somata, in the AZ are immunoreactive, whereas both PC somata and dendrites were
immunoreactive in the NZ. Furthermore, there were striped expression patterns in lobules VIII and IX
(i.e., PZ), whereas a uniform expression was evident in PCs of lobule X (i.e., NZ). These patterns of
zone and stripes are clearer at P17 in the nax cerebellum. DRD4 immunoreactivity of PCs displays
the stripes pattern of expression in lobules III and IX but a uniform expression in lobule X in nax
cerebella. This indicates that DRD4 is expressed in a stripe pattern in the wt cerebellum, but the clear
appearance of a stripes pattern in nax cerebellum, particularly in the AZ, is probably because of the
decreased number of stripes in nax mice [16]. It has been reported previously that only a faint DRD4
immunoreactivity is present in the ml, associated with structures resembling climbing fibers, PCs,
and stellate neurons of ml [53].
In our study, DRD5 protein and gene expression patterns during cerebellar development were
comparable between the wt and nax group. Immunoperoxidase staining on P5 showed a weak
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immunoreactivity of DRD5 in the Pcl in wt and nax cerebella. By P17, DRD5 immunoperoxidase
staining showed weak immunoreactivity in PCs in the wt and nax cerebellum. A study by Barili and
colleagues showed a faint DRD5 immunoreactivity in the cerebellar white matter of rats, suggesting
these receptors may be presynaptic and transported through axons to the cortical layers [53].
In a final note, it is important to discuss the possibility of the involvement of the cell recycling
process, macroautophagy (hereafter, autophagy), and mechanism of the cell in response to cellular stress,
unfolded protein response, and its possible involvements in our observations. Acp2 is a lysosomal
enzyme which might be involved in the regulation of lysosomal activity [54] and a possible indirect
effect in the regulation of autophagy. It is a strong possibility that mutated Acp2 can potentially affect
the autophagy flux and the trafficking of the protein degradation by lysosomes (e.g., Supplementary
Materials). Our results showed that ACP2 point mutation can not only affect autophagosome recycling
(LC3β lipidation) but also can affect expression of the essential proteins which are involved in different
stages of autophagy Beclin–1, Atg7). As a result, we potentially have the defect of lysosomal protein
degradation in nax animals due to a malfunction of lysosomal activity. Therefore, it is possible that our
observations regarding the mismatch of RNAseq results and protein expressions of DRDs were due to
a defect of autophagy and lysosomal protein degradation in the nax model. On the other hand, our
recent investigations have showed that unfolded protein response UPR is a regulator of autophagy in
many models [55–57]. It is very probable that mutated/misfolded Acp2 induced UPR and indirectly
affected the autophagy and lysosomal activity and downregulated the lysosomal protein degradation
and, subsequently, downregulated the DRD degradation. At present, my team is focused on the
regulation of UPR and autophagy in a nax model and its possible effects in intracellular trafficking and
affecting early development.
5. Conclusions
In conclusion, our comparative study on dopamine receptor subtype expression in the developing
cerebella of nax and wt mice showed no significant differences in DRD1–5 protein expression levels but
did reveal significant upregulations in Drd1, Drd3, and Drd4 gene expression in nax cerebella. It seems
that Drd2 and Drd5 gene expression have no dependency on ACP2. With regard to differential DRD
expressions, the most interesting observation included the lack of or very weak DRD3 expression in
Golgi cells and the more pronounced DRD4 stripe expression pattern in the nax cerebellum. Alterations
in cerebellar DRD expression levels, most noticeably in DRD3 and –4, may have resulted from an Acp2
mutation and may therefore play a role in cerebellar development and the control of movement.
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